<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CLOZAPINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CLOZAPINE</h1>

        <p><a href="../drugClass/PHP34569.html">ANTIPSYCHOTIC DRUGS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;59 years</strong><br/>
                12.5 mg 1&#8211;2 times a day for day 1, then 25&#8211;50 mg for day 2, then increased, if tolerated, in steps of 25&#8211;50 mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300 mg daily in divided doses, larger dose to be taken at night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100 mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day.</li>
              <li class="dose adult"><strong>For adults 60 years and over</strong><br/>
                12.5 mg once daily for day 1, then increased to 25&#8211;37.5 mg for day 2, then increased, if tolerated, in steps of up to 25 mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300 mg daily in divided doses, larger dose at to be taken night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100 mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Psychosis in Parkinson's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                12.5 mg once daily, dose to be taken at bedtime, then increased in steps of 12.5 mg up to twice weekly, adjusted according to response; usual dose 25&#8211;37.5 mg once daily, dose to be taken at bedtime; increased in steps of 12.5 mg once weekly, this applies only in exceptional cases, increased if necessary up to 100 mg daily in 1&#8211;2 divided doses; Usual maximum 50 mg/24 hours.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>
            </section>
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>
            <b>Clozapine</b> is a dopamine D<sub>1</sub>, dopamine D<sub>2</sub>, 5-HT<sub>2A</sub>, alpha<sub>1</sub>-adrenoceptor, and muscarinic-receptor antagonist.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use with caution.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in symptomatic liver disease.</p><p>Avoid in progressive liver disease.</p><p>Avoid in hepatic failure.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Alcoholic and toxic psychoses</li>
            <li>bone-marrow disorders</li>
            <li>coma</li>
            <li>drug intoxication</li>
            <li>history of agranulocytosis</li>
            <li>history of circulatory collapse</li>
            <li>history of neutropenia</li>
            <li>paralytic ileus</li>
            <li>severe cardiac disorders (e.g. myocarditis)</li>
            <li>severe CNS depression</li>
            <li>uncontrolled epilepsy</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Anorexia, constipation, hypersalivation, malaise, speech disorders, urinary incontinence,
              </p>
              <p>
                <strong>uncommon:</strong> Agranulocytosis,
              </p>
              <p>
                <strong>rare:</strong> Circulatory collapse, dysphagia, hepatitis, myocarditis, pancreatitis, pericarditis, pneumonia, pulmonary aspiration,
              </p>
              <p>
                <strong>veryRare:</strong> Cardiomyopathy, hypercholesterolaemia, hypertriglyceridaemia, interstitial nephritis, intestinal obstruction (including fatal cases), myocardial infarction, obsessive compulsive disorder, parotid gland enlargement, respiratory depression,
              </p>
              <p>
                <strong>notKnown:</strong> Hepatic disorders, hepatic failure, muscle disorders, renal failure,
              </p>
        
        
            <section class="advice">
                <h3>Hypersalivation</h3>
              <p>Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication], provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients or carers should be given advice on how to administer clozapine oral suspension.</p>
            </section>
            <section class="patientResources">
              <p>A patient information leaflet should be provided.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Age over 60 years
          </li>
          <li>
            prostatic hypertrophy
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
            taper off other antipsychotics before starting
          </li>
        </ul>
        <ul>
          <li>
            <p>Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000&#8239;/mm<sup>3</sup> or if absolute neutrophil count below 1500&#8239;/mm<sup>3</sup> discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.</p>
          </li>
          <li>
            <p>Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.</p><ul>
        <li>Perform physical examination and take full medical history before starting</li>
        <li>Specialist examination required if cardiac abnormalities or history of heart disease found&#8212;clozapine initiated only in absence of severe heart disease and if benefit outweighs risk</li>
        <li>Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy</li>
        <li>If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist</li>
        <li>Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy</li>
        </ul>
          </li>
          <li>
            <p>Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.</p><p>Close medical supervision during initiation (risk of collapse because of hypotension and convulsions).</p><p>Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.</p><p>Fasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.</p>
            </section>
      </section>



      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>On planned withdrawal reduce dose over 1&#8211;2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CLOZAPINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP74628"><a href="../medicinalForm/PHP74628.html" data-target="#PHP74628" data-action="load">Tablet</a></div>
            <div id="PHP74633"><a href="../medicinalForm/PHP74633.html" data-target="#PHP74633" data-action="load">Oral suspension</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
